Applied Molecular Transport engages advisor to explore strategic alternatives

Applied Molecular Transport announced that the company has engaged MTS Health Partners as advisors in a process to explore strategic alternatives for the company. "We continue to believe our proprietary technology, that enables the design of novel oral biologics, is an important innovation in the field of therapeutics." said Cross. "However, after an extensive assessment of our clinical programs and the current business environment, we have made the difficult decision to pause research and development as we close out existing programs and explore ending the AMT-101 Castro trial in Rheumatoid Arthritis at its current enrollment. In parallel, we are in the process of exploring strategic alternatives that may allow for further development of our clinical and earlier-stage programs with internal resources or via partnerships. We are deeply grateful to our go-forward team, recently departed colleagues, and founding scientists, including Tahir, for the innovation and advancement of our proprietary technology platform and dedication to AMT."